Term ended Aug 19, 2025 · Medium confidence
20-year base term ended May 7, 2024
Held by AbbVie Biotherapeutics Inc.
Filed Sep 22, 2015 as application 14/860,906 · Granted Oct 15, 2019
Base term plus 469 days of patent term adjustment (USPTO delay)
Today
Term ended Aug 19, 2025
2004
2026
Clock starts
May 7, 2004
May 7, 2004
Term ended
Aug 19, 2025
Aug 19, 2025
Granted
Oct 15, 2019
Oct 15, 2019
base term
patent term adjustment
after the term ends
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
469
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,709,610, to Aug 19, 2025. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
6
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 469 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 7, 2004, when application 10/842,011, the earliest non-provisional in its chain, was filed (this one was filed Sep 22, 2015); a parent in its chain could not be resolved (the next row) | May 7, 2024 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +469 days, USPTO patent term adjustment record | Aug 19, 2025 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,709,610) | resolves to Aug 19, 2025, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 1 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Aug 19, 2025 | Medium confidence |
Partial family
| Application 10/842,011 | Abandoned not computed | not computed |
| US 7,709,610 | In force no later than Aug 2029 | no later than Aug 2029 |
| US 8,008,450 | Term ended no later than May 2024 | no later than May 2024 |
| US 8,445,646 | Term ended no later than May 2024 | no later than May 2024 |
| US 9,175,081 | Term ended no later than May 2024 | no later than May 2024 |
| US 10,442,859 | this patent Aug 2025 | Aug 2025 |
Partial: 2 of the 6 have no file history here, so a row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 13, 2015 Reel 37031, frame 929 | Williams, Marna; Tso, J. Yun; Landolfi, Nicholas F. | Protein Design Labs, Inc. | Assignment of Assignor's Interest |
| Nov 13, 2015 Reel 37033, frame 603 | PDL Biopharma, Inc. | Facet Biotech Corporation | Assignment of Assignor's Interest |
| Nov 13, 2015 Reel 37033, frame 478 | Liu, Gao | PDL Biopharma | Assignment of Assignor's Interest |
| Nov 13, 2015 Reel 37034, frame 115 | Abbott Biotherapeutics Corp. | AbbVie Biotherapeutics Inc. | Change of Name |
| Nov 13, 2015 Reel 37111, frame 396 | Protein Design Labs, Inc. | PDL Biopharma, Inc. | Change of Name |
| Nov 13, 2015 Reel 37111, frame 410 | Facet Biotech Corporation | Abbott Biotherapeutics Corp. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
The 469 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,709,610, ends no earlier than this term, so it caps nothing.
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.